NCT04879836

Brief Summary

Teething discomfort is a widespread disorder affecting a very high percentage of infants. The use of hyaluronic acid gels has been shown in the last 20 years to be an effective tool, generally devoid of side effects, in reducing oral mucosal inflammation in adults. Its effectiveness in infants is affected by the strength of hyaluronic acid retention over the oral mucosa. This is in turn affected by formulation and may vary between different products due to the different ingredients used. In this study, the results collected by monitoring the paediatric experience regarding a newly developed HA-based medical device, intended to counteract teething discomfort in infants, will be reported.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

May 4, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 10, 2021

Completed
Last Updated

July 7, 2021

Status Verified

July 1, 2021

Enrollment Period

7 months

First QC Date

May 4, 2021

Last Update Submit

July 6, 2021

Conditions

Keywords

gumsrednessfeverpaediatricinappetencesleep disturbance

Outcome Measures

Primary Outcomes (8)

  • Unexplained cry

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Irritability

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Sleep disturbance

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Inappetence

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Salivation

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Gum redness

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

  • Fever

    Number of days with fever

    1 month (1 check per week)

  • General well-being

    5-level Likert scale completed by the paediatrician

    1 month (1 check per week)

Study Arms (2)

Teething Ring + Teething Gel

Device: Teething GelDevice: Teething Ring

Teething Ring

Device: Teething Ring

Interventions

Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks

Teething Ring + Teething Gel

The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks

Teething RingTeething Ring + Teething Gel

Eligibility Criteria

Age2 Months - 12 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Infants, without ethnic limitations, of both sexes and between the ages of 2 and 12 months, affected by teething discomfort but considered otherwise healthy.

You may qualify if:

  • Teething discomfort
  • Being healthy (except for teething discomfort)

You may not qualify if:

  • Being placed on one of the following therapies in the 45 days prior to the beginning of the study: immunosuppressive, cytotoxic, cortisone, antibiotics, antifungal and hormone therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Urbino Carlo Bo

Urbino, 61029, Italy

Location

MeSH Terms

Conditions

ErythemaFeverAnorexiaParasomnias

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue DiseasesSkin ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsBody Temperature ChangesSigns and Symptoms, DigestiveSleep Wake DisordersNervous System DiseasesMental Disorders

Study Officials

  • Davide Sisti, PhD

    University of Urbino "Carlo Bo"

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

May 4, 2021

First Posted

May 10, 2021

Study Start

December 1, 2018

Primary Completion

June 30, 2019

Study Completion

June 30, 2019

Last Updated

July 7, 2021

Record last verified: 2021-07

Locations